Literature DB >> 29652730

Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation.

Karl Fengler1, Karl-Philipp Rommel, Stephan Blazek, Maximilian von Roeder, Christian Besler, Philipp Hartung, Steffen Desch, Holger Thiele, Philipp Lurz.   

Abstract

BACKGROUND: Renal sympathetic denervation (RDN) as treatment for hypertension shows highly variable results. Although some patients do not show any blood pressure (BP) change and in most patients a BP reduction of at least 5 mmHg can be found, some show a reduction at least 20 mmHg. We sought to identify predictors for such a profound BP response.
METHODS: Profound BP response was defined as drop of at least 20 mmHg in daytime systolic ambulatory BP measurement (ABPM) 3 months after catheter-based RDN. Three different denervation devices were used for RDN, and pulse wave velocity was determined invasively in a subgroup of patients.
RESULTS: One hundred and ninety consecutive patients were included in this analysis. Profound BP response was found in 33 patients. Patients with profound BP response were younger (P = 0.04), presented with higher baseline ABPM values (P < 0.001), were treated with ultrasound-based RDN and received more often a combined treatment with two different diuretics (P = 0.005 for both). After 3 months, a treatment target of daytime BP less than 135 mmHg could be achieved more frequently in patients with profound BP response (61 vs. 17%, P < 0.001). Age, use of ultrasound RDN, combined diuretic therapy and baseline BP independently predicted pronounced BP reduction. A second multivariate logistic regression model including pulse wave velocity if available identified baseline BP, pulse wave velocity and use of ultrasound denervation as independent predictors for profound BP response.
CONCLUSION: Younger vascular age, higher baseline BP, treatment with ultrasound RDN and combined diuretic therapy were found as predictors for a pronounced BP reduction following RDN, improving BP control at follow-up.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29652730     DOI: 10.1097/HJH.0000000000001739

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Renal Artery Denervation for Hypertension.

Authors:  Lauren S Ranard; Rajesh V Swaminathan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-02-14

2.  2022 Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension.

Authors:  Yook Chin Chia; Wan Azman Wan Ahmad; Alan Yean Yip Fong; Azhari Rosman; Abdul Rashid Abdul Rahman; Gim Hooi Choo; Soo Kun Lim; Mohammad Zawawi Abu Bakar; Tiong Kiam Ong
Journal:  Hypertens Res       Date:  2022-06-01       Impact factor: 5.528

3.  Comparison of Long-Term Outcomes for Responders Versus Non-Responders Following Renal Denervation in Resistant Hypertension.

Authors:  Karl Fengler; Paul Reimann; Karl-Philipp Rommel; Karl-Patrik Kresoja; Stephan Blazek; Matthias Unterhuber; Christian Besler; Maximilian von Roeder; Michael Böhm; Steffen Desch; Holger Thiele; Philipp Lurz
Journal:  J Am Heart Assoc       Date:  2021-10-29       Impact factor: 5.501

Review 4.  Predicting Renal Denervation Response in Resistant High Blood Pressure by Arterial Stiffness Assessment: A Systematic Review.

Authors:  Alexandru Burlacu; Crischentian Brinza; Mariana Floria; Anca Elena Stefan; Andreea Covic; Adrian Covic
Journal:  J Clin Med       Date:  2022-08-18       Impact factor: 4.964

5.  Predictors for success in renal denervation-a single centre retrospective analysis.

Authors:  Alexander Reshetnik; Christopher Gohlisch; Christian Scheurig-Münkler; Maximilian De Bucourt; Walter Zidek; Markus Tölle; Markus van der Giet
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

6.  Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study.

Authors:  Manish Saxena; Roland E Schmieder; Ajay J Kirtane; Felix Mahfoud; Joost Daemen; Jan Basile; Philipp Lurz; Philippe Gosse; Kintur Sanghvi; Naomi D L Fisher; Lars C Rump; Atul Pathak; Peter J Blankestijn; Anthony Mathur; Yale Wang; Michael A Weber; Andrew S P Sharp; Michael J Bloch; Neil C Barman; Lisa Claude; Yang Song; Michel Azizi; Melvin D Lobo
Journal:  J Hum Hypertens       Date:  2021-05-24       Impact factor: 2.877

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.